Physician profile
William Clark Decker
NPI 1942205208
$10,135.57
in general payments reported to CMS, 2019-2025
43 companies · $1,580 in 2025
The $1,580 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,185 · 2020: $1,340 · 2021: $1,285 · 2022: $1,694 · 2023: $1,535 · 2024: $1,516 · 2025: $1,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,608 · Education: $23.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,607.93 |
| Education | $23.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,823.81 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Mylan Specialty L.P. | $1,281.76 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $1,085.43 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,081.24 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $899.65 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $581.11 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $305.39 | 2020-2025 | Cuvitru, Hyqvia |
| Insmed, INC. | $299.54 | 2022-2025 | Arikayce, Brinsupri |
| Csl Behring | $283.63 | 2019-2025 | Hizentra |
| Janssen Pharmaceuticals, INC | $231.81 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $209.45 | 2019-2024 | Eliquis |
| Pfizer INC. | $191.54 | 2022-2025 | |
| Genentech USA, INC. | $190.66 | 2019-2022 | |
| United Therapeutics Corporation | $144.75 | 2021-2025 | Tyvaso, Tyvaso |
| Paratek Pharmaceuticals, INC. | $140.14 | 2020-2025 | Nuzyra |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $122.47 | 2025 | Zepbound, Mounjaro |
| Grifols USA, LLC | $115.21 | 2019-2024 | Prolastin-C Liquid |
| Viatris Specialty LLC | $91.25 | 2025 | Yupelri |
| Inogen, INC. | $83.68 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Sanofi-Aventis U.S. LLC | $81.99 | 2022 | |
| Amgen INC. | $81.13 | 2022-2025 | Tezspire |
| Baxter Healthcare | $70.69 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Novo Nordisk INC | $63.60 | 2021-2025 | Wegovy |
| Verona Pharma, INC. | $62.85 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $60.94 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $59.88 | 2021-2025 | Uptravi, Opsumit |
| Teva Pharmaceuticals USA, INC. | $57.03 | 2020 | |
| Electromed, INC. | $47.92 | 2023-2025 | Smartvest |
| Inspire Medical Systems, INC. | $46.42 | 2024 | Inspire |
| Advanced Respiratory, INC | $42.98 | 2019-2021 | |
| Philips North America LLC | $38.74 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $34.58 | 2020 | |
| Circassia INC. | $31.83 | 2019 | |
| Harmony Biosciences LLC | $31.46 | 2023 | Wakix |
| Merck Sharp & Dohme LLC | $30.77 | 2019-2024 | |
| Avadel Cns Pharmaceuticals, LLC | $20.90 | 2025 | Lumryz |
| Nestle Healthcare Nutrition INC. | $18.26 | 2022 | |
| Mallinckrodt Enterprises LLC | $17.16 | 2019 | |
| Melinta Therapeutics, LLC | $16.30 | 2023 | Rezzayo, Vabomere |
| 3b Medical, INC. | $15.53 | 2024 | Luna |
| Phadia US INC. | $14.48 | 2024 | Immunocap |
| Pulmonx Corporation | $13.84 | 2021 | |
| La Jolla Pharmaceutical Company | $13.77 | 2023 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Decker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.